In Vitro Activity of Ceftazidime-Avibactam against 338 Molecularly Characterized Gentamicin-Nonsusceptible Gram-Negative Clinical Isolates Obtained from Patients in Canadian Hospitals | Zendy

Andrew Denisuik | Zendy; James A. Karlowsky | Zendy; Tyler Denisuik | Zendy; Wright W. Nichols | Zendy; Thomas A. Keating | Zendy; Heather J. Adam | Zendy; Melanie Baxter | Zendy; Andrew Walkty | Zendy; George G. Zhanel | Zendy

Open Access

In Vitro Activity of Ceftazidime-Avibactam against 338 Molecularly Characterized Gentamicin-Nonsusceptible Gram-Negative Clinical Isolates Obtained from Patients in Canadian Hospitals

Author(s) -

Andrew Denisuik,

James A. Karlowsky,

Tyler Denisuik,

Wright W. Nichols,

Thomas A. Keating,

Heather J. Adam,

Melanie Baxter,

Andrew Walkty,

George G. Zhanel

Publication year - 2015

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.00364-15

Subject(s) - ceftazidime/avibactam , gentamicin , ceftazidime , gram , microbiology and biotechnology , avibactam , medicine , antibiotics , in vitro , gram negative bacteria , chemistry , biology , bacteria , pseudomonas aeruginosa , escherichia coli , genetics , gene

The mechanism of aminoglycoside resistance among 338 gentamicin-nonsusceptible Gram-negative bacteria (207Enterobacteriaceae and 131Pseudomonas aeruginosa ) was assessed, and thein vitro activity of ceftazidime-avibactam against these isolates was determined. Aminoglycoside-modifying enzymes were detected in 91.8% ofEnterobacteriaceae and 13.7% ofP. aeruginosa isolates. A single strain ofKlebsiella pneumoniae harbored a 16S rRNA methylase (ArmA). The ceftazidime-avibactam MIC90 values were 0.5 μg/ml (MIC, ≤8 μg/ml for 100% of isolates) and 16 μg/ml (MIC, ≤8 μg/ml for 87.8% of isolates) against gentamicin-nonsusceptibleEnterobacteriaceae andP. aeruginosa isolates, respectively.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research